{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:04:14Z","timestamp":1776272654285,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No. 2019CFB368"],"award-info":[{"award-number":["No. 2019CFB368"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No. 2020CFB364"],"award-info":[{"award-number":["No. 2020CFB364"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-024-05243-7","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T01:29:40Z","timestamp":1733448580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical significance of dynamic monitoring of EVI1 gene expression in pediatric acute myeloid leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Lan-Nan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Shan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Zheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"5243_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2021.12.398","volume":"107","author":"R Paredes","year":"2022","unstructured":"Paredes R, Doleschall N, Connors K, et al. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?. Exp Hematol. 2022;107:1\u20138.","journal-title":"Exp Hematol"},{"issue":"3","key":"5243_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","volume":"11","author":"C Birdwell","year":"2021","unstructured":"Birdwell C, Fiskus W, Kadia TM, et al. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021;11(3):64.","journal-title":"Blood Cancer J"},{"issue":"5","key":"5243_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/sj.onc.1200864","volume":"14","author":"C Bartholomew","year":"1997","unstructured":"Bartholomew C, Kilbey A, Clark AM, et al. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene. 1997;14(5):569\u201377.","journal-title":"Oncogene"},{"issue":"6","key":"5243_CR4","doi-asserted-by":"publisher","first-page":"e66510","DOI":"10.1371\/journal.pone.0066510","volume":"8","author":"DJ White","year":"2013","unstructured":"White DJ, Unwin RD, Bindels E, et al. Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability. PLoS ONE. 2013;8(6):e66510.","journal-title":"PLoS ONE"},{"issue":"12","key":"5243_CR5","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1084\/jem.20110447","volume":"208","author":"K Kataoka","year":"2011","unstructured":"Kataoka K, Sato T, Yoshimi A, et al. EVI1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011;208(12):2403\u201316.","journal-title":"J Exp Med"},{"issue":"14","key":"5243_CR6","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1182\/blood-2011-02-334680","volume":"118","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Stehling-Sun S, Lezon-Geyda K, et al. PR-domain-containing Mds1-EVI1 is critical for long-term hematopoietic stem cell function. Blood. 2011;118(14):3853\u201361.","journal-title":"Blood"},{"issue":"1","key":"5243_CR7","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1038\/s41467-018-06208-y","volume":"9","author":"E Ayoub","year":"2018","unstructured":"Ayoub E, Wilson MP, McGrath KE, et al. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. Nat Commun. 2018;9(1):4239.","journal-title":"Nat Commun"},{"issue":"7","key":"5243_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/j.1349-7006.2008.00842.x","volume":"99","author":"T Sato","year":"2008","unstructured":"Sato T, Goyama S, Nitta E, et al. Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-b signaling. Cancer Sci. 2008;99(7):1407\u201313.","journal-title":"Cancer Sci"},{"issue":"49","key":"5243_CR9","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1038\/onc.2009.288","volume":"28","author":"M Shimabe","year":"2009","unstructured":"Shimabe M, Goyama S, Watanabe-Okochi N, et al. Pbx1 is a downstream target of Evi-1 in hematopoietic stem\/progenitors and leukemic cells. Oncogene. 2009;28(49):4364\u201374.","journal-title":"Oncogene"},{"issue":"13","key":"5243_CR10","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","volume":"117","author":"A Yoshimi","year":"2011","unstructured":"Yoshimi A, Goyama S, Watanabe-Okochi N, et al. EVI1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins. Blood. 2011;117(13):3617\u201328.","journal-title":"Blood"},{"issue":"5","key":"5243_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood.2022016592","volume":"141","author":"J Schmoellerl","year":"2023","unstructured":"Schmoellerl J, Barbosa IAM, Minnich M, et al. EVI1 drives leukemogenesis through aberrant ERG activation. Blood. 2023;141(5):453\u201366.","journal-title":"Blood"},{"issue":"2","key":"5243_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/gcc.23004","volume":"61","author":"J Gao","year":"2022","unstructured":"Gao J, Gurbuxani S, Zak T, et al. Comparison of myeloid neoplasms with nonclassic 3q26.2\/MECOM versus classic inv(3)\/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation. Genes Chromosomes Cancer. 2022;61(2):71\u201380.","journal-title":"Genes Chromosomes Cancer"},{"issue":"20","key":"5243_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"11","key":"5243_CR14","first-page":"877","volume":"44","author":"Subspecialty Group of Hematology Diseases, Society of Pediatrics, Chinese Medical Association","year":"2006","unstructured":"Subspecialty Group of Hematology Diseases, Society of Pediatrics, Chinese Medical Association. Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood. Chin J Pediatr. 2006;44(11):877\u20138.","journal-title":"Chin J Pediatr"},{"key":"5243_CR15","doi-asserted-by":"crossref","unstructured":"Li J, Gao J, Liu A et al. Homoharringtonine-based induction regimen improved the Remission Rate and Survival Rate in Chinese Childhood AML: a Report from the CCLG-AML 2015 protocol Study [published online ahead of print, 2023 Aug 2]. J Clin Oncol. 2023;JCO2202836.","DOI":"10.1200\/JCO.22.02836"},{"issue":"7","key":"5243_CR16","first-page":"653","volume":"35","author":"B Wang","year":"2014","unstructured":"Wang B, Yang B, Dong W, et al. Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations. Zhonghua Xue Ye Xue Za Zhi. 2014;35(7):653\u20135.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"12","key":"5243_CR17","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021011694","volume":"138","author":"JE Rubnitz","year":"2021","unstructured":"Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138(12):1009\u201318.","journal-title":"Blood"},{"issue":"1","key":"5243_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/blood-2008-11-187724","volume":"114","author":"MC Chill\u00f3n","year":"2009","unstructured":"Santam7ar\u00eda CM, Chill\u00f3n MC, Garc\u00eda-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood. 2009;114(1):148\u201352.","journal-title":"Blood"},{"issue":"2","key":"5243_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41409-020-01048-1","volume":"56","author":"S Jiang","year":"2021","unstructured":"Jiang S, Fan Y, Fang Y, et al. The role of EVI1 gene quantification in AML patients with 11q23\/MLL rearrangement after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2021;56(2):470\u201380.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"5243_CR20","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00277-019-03774-z","volume":"98","author":"X Wu","year":"2019","unstructured":"Wu X, Wang H, Deng J, et al. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Ann Hematol. 2019;98(11):2485\u201396.","journal-title":"Ann Hematol"},{"issue":"5","key":"5243_CR21","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/leu.2010.47","volume":"24","author":"BV Balgobind","year":"2010","unstructured":"Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"5243_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/0284186X.2022.2025611","volume":"61","author":"M Elsherif","year":"2022","unstructured":"Elsherif M, Hammad M, Hafez H, et al. MECOM gene overexpression in pediatric patients with acute myeloid leukemia. Acta Oncol. 2022;61(4):516\u201322.","journal-title":"Acta Oncol"},{"key":"5243_CR23","doi-asserted-by":"publisher","first-page":"107019","DOI":"10.1016\/j.leukres.2023.107019","volume":"126","author":"R Nabil","year":"2023","unstructured":"Nabil R, Abdellateif MS, Gamal H, et al. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia. Leuk Res. 2023;126:107019.","journal-title":"Leuk Res"},{"issue":"1","key":"5243_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/16078454.2021.1880734","volume":"26","author":"C Chen","year":"2021","unstructured":"Chen C, Chio CL, Zeng H, et al. High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia. Hematology. 2021;26(1):210\u20134.","journal-title":"Hematology"},{"key":"5243_CR25","doi-asserted-by":"crossref","unstructured":"Iriyama N, Hatta Y, Takeuchi J CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t (8;21) . Leuk Res, Panda D, Chatterjee G, Sardana R et al. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom, 2021. 100(2): 206\u2013217.","DOI":"10.1002\/cyto.b.21943"},{"key":"5243_CR26","doi-asserted-by":"crossref","unstructured":"Panda D, Chatterjee G, Sardana R, et al. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom, 2021. 100(2): 206\u2013217.","DOI":"10.1002\/cyto.b.21943"},{"key":"5243_CR27","doi-asserted-by":"publisher","first-page":"106603","DOI":"10.1016\/j.leukres.2021.106603","volume":"107","author":"REE Hoch","year":"2021","unstructured":"Hoch REE, C\u00f3ser VM, Santos IS, et al. Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia. Leuk Res. 2021;107:106603.","journal-title":"Leuk Res"},{"issue":"12","key":"5243_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"1","key":"5243_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.19518","volume":"205","author":"C Jim\u00e9nez-Vicente","year":"2024","unstructured":"Jim\u00e9nez-Vicente C, Charry P, Casta\u00f1o-Diez S, et al. Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: identification of a very poor prognosis genetic group. Br J Haematol. 2024;205(1):256\u201367.","journal-title":"Br J Haematol"},{"issue":"6","key":"5243_CR30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/genes12060924","volume":"12","author":"J Quessada","year":"2021","unstructured":"Quessada J, Cuccuini W, Saultier P, et al. Cytogenetics of Pediatric Acute myeloid leukemia: a review of the current Knowledge. Genes (Basel). 2021;12(6):924.","journal-title":"Genes (Basel)"},{"issue":"6","key":"5243_CR31","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41375-018-0314-7","volume":"33","author":"AMJ Reedijk","year":"2019","unstructured":"Reedijk AMJ, Klein K, Coebergh JWW, et al. Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia. 2019;33(6):1349\u201359.","journal-title":"Leukemia"},{"issue":"6","key":"5243_CR32","first-page":"990","volume":"49","author":"WB Duan","year":"2017","unstructured":"Duan WB, Gong LZ, Jia JS, et al. Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive. Beijing Da Xue Xue Bao Yi Xue Ban. 2017;49(6):990\u20135.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"21","key":"5243_CR33","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1158\/1078-0432.CCR-23-1429","volume":"29","author":"J Senapati","year":"2023","unstructured":"Senapati J, Fiskus WC, Daver N, et al. Phase I results of Bromodomain and extra-terminal inhibitor PLX51107 in combination with azacitidine in patients with Relapsed\/Refractory myeloid Malignancies. Clin Cancer Res. 2023;29(21):4352\u201360.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5243_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41375-023-02108-3","volume":"38","author":"CE Birdwell","year":"2024","unstructured":"Birdwell CE, Fiskus W, Kadia TM, et al. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024;38(3):545\u201356.","journal-title":"Leukemia"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-024-05243-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05243-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T02:03:48Z","timestamp":1733450628000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-024-05243-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5243"],"URL":"https:\/\/doi.org\/10.1186\/s12887-024-05243-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4490141\/v1","asserted-by":"object"}]},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the diagnostic methods and chemotherapy regimens conform to the principles outlined in the Declaration of Helsinki. The studies involving human participants were reviewed and approved by the Wuhan Women\u2019s and Children\u2019s Health Care Center Ethics Committee. Informed written consent was obtained from the parents or guardians as appropriate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"802"}}